Following the conclusion of the Doctors Forum, Market Institute hosted a Site Neutrality Happy Hour to illustrate healthcare payment disparities in a tangible, real-world way. Congressional staff and Members of Congress were invited to participate in a hands-on demonstration designed to show how price differences—rather than quality or outcomes—drive behavior Read more…
The recent Congressional hearing on drug prices, patents, and the pharmaceutical industry has ignited a fervent debate. Unfortunately, much of the discourse has been overshadowed by misunderstandings and misinformation. A nuanced comprehension of the patent system and its pivotal role in drug innovation is essential for fostering informed discussions and Read more…
This week, 16 conservative think tanks and advocacy groups organized a coalition letter in opposition to the Biden Administration’s recent efforts to undermine the Medicare Advantage (MA) program. The letter argues that, in addition to being an extremely popular and more efficient form of coverage, Medicare Advantage stands as a protection against Read more…
In the realm of healthcare politics, a glaring power dynamic emerges: giant corporations, notably hospitals, wield disproportionate influence over policy decisions and spending. A new article in Inside Sources by Charles Sauer explores the contentious issue of “Site Neutral” payment reform, revealing how this policy discrepancy enables hospitals to charge Read more…
In a recent turn of events, Senator Bernie Sanders has raised eyebrows by calling for the subpoena of two drug company CEOs, sparking both curiosity and concern. Market Institute President Charles Sauer’s new article in Townhall delves into Sanders’ unconventional tactics, questioning the wisdom of his confrontational approach to the Read more…
In a letter addressed to Congress, and organized by Competitive Enterprise Institute, the undersigned organizations express their strong concerns regarding the Inflation Reduction Act (IRA), particularly its provisions related to prescription drug price controls. The coalition argues that the IRA’s prescription drug price control regime is unnecessary, as it focuses Read more…
The Market Institute President Charles Sauer has a new article in Real Clear Policy looking at the problems with price setting drug prices. There are attempts by the Biden Administration to use “March In” rights to implement price controls – even at the expense of future innovation. He writes: “In Read more…
The Market Institute President Charles Sauer a new article out in The Washington Examiner highlighting the successes of deregulation during the pandemic, including the proliferation of telehealth. He writes: “Like almost everything in life, the good often comes with the bad. Taylor Swift songs come with an annoying fan base, Read more…
The Market Institute President Charles Sauer has a new article in Real Clear Health highlighting a recent executive order by the Biden Administration to use antitrust enforcement. “In a move that would warm Joseph Stalin’s dead heart, the Biden Administration released (yet) another Executive Order, this one instructing federal agencies to ramp Read more…
Market Institute President Charles Sauer has a new piece in RealClear Policy on patent rights. The White House recently issued a patent waiver for Covid-19 vaccines. Here’s an excerpt of Sauer’s article: “President Biden recently made what the Wall Street Journal referred to as the worst single Presidential decision since Nixon’s Read more…